Skip to main content
Real GLP-1

Weight, appetite, and the rest of the result

Reading list

Studies and reviews

The weight result is the beginning of this list. The questions spread out from there.

Where to begin

STEP 1 supplies the weight-loss comparison. My next stops would be SELECT and FLOW for the cardiovascular and kidney outcomes that widened my interest. The heart-failure trial adds symptoms and physical limitations to the conversation.

The rodent neural-pathway study is the most surprising appetite paper on this list to me. It sits beside a mechanistic review and an early human alcohol-use-disorder trial, each asking a different question. For the cautions, start with the safety review and the SUSTAIN-6 cardiovascular and retinopathy findings.

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity ↗
  2. Semaglutide lowers body weight in rodents via distributed neural pathways ↗
  3. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ↗
  4. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes ↗
  5. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes ↗
  6. Safety of Semaglutide ↗
  7. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity ↗
  8. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial ↗
  9. Spotlight on the Mechanism of Action of Semaglutide ↗